Scientists seek perfect dose for DMD heart drug
NCT ID NCT07172971
Summary
This study aims to understand how a heart medication called empagliflozin is processed by the bodies of children with Duchenne muscular dystrophy (DMD). Researchers will give the drug to 10 young DMD patients of different ages and sizes and measure its levels in their blood over 24 hours. The goal is to gather information to determine the safest and most effective dose for future studies aimed at treating DMD-related heart disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Riley Hospital at Indiana University Health
Indianapolis, Indiana, 46202, United States
Conditions
Explore the condition pages connected to this study.